key: cord-0825180-rttn64uu
authors: Veraldi, Stefano; Spigariolo, Cristina B.
title: Pityriasis rosea and COVID‐19
date: 2020-12-01
journal: J Med Virol
DOI: 10.1002/jmv.26679
sha: 239d27511d79e64cfa162e171620316a69634135
doc_id: 825180
cord_uid: rttn64uu

We read with interest the letter by Drago et al. on the reactivation of human herpes virus (HHV)-6, HHV-7 and Epstein-Barr virus (EBV) in a boy with Coronavirus disease-19 (COVID-19).1 This article is protected by copyright. All rights reserved.

To the Editor,

We read with interest the letter by Drago et al. 1 on the reactivation of human herpes virus 6 (HHV-6), HHV-7, and Epstein-Barr virus (EBV) in a boy with coronavirus disease-19 (COVID-19).

We wish to report our experience on the relationship pityriasis rosea (PR)-COVID-19. We observed two cases of typical PR, which appeared approximately 6 weeks following the first clinical manifestations of COVID-19. The first patient was a 26-year-old Caucasian girl who developed, in March 2020, cough, fever (<37.8°C), severe weakness, anosmia, and dysgeusia. Laboratory examinations revealed lymphopenia (1.600 lymphocytes/mmc = 11%). Nasal swab was positive for severe acute respiratory syndrome coronavirus 2 RNA (SARS-CoV-2 RNA). The patient was treated only with paracetamol.

Two nasal swabs were negative in April 2020. Laboratory tests confirmed lymphopenia. In May 2020, the patient developed a typical PR.

The patient is currently well, except for anosmia. The second patient was a 25-year-old Caucasian man who developed, in July 2020, headache, weakness, drowsiness, arthralgia, myalgia, and fever (<38.2°C). Laboratory tests showed leucopenia, lymphopenia (1.300 lymphocytes/mmc = 9%), with reduced CD4+ and CD8+ T cells, and a mild increase in erythrocyte sedimentation rate. Nasal swab was positive for SARS-CoV-2 RNA. Chest X-rays were negative. The patient was followed at his home and treated only with paracetamol.

Three weeks later, total anti-N SARS-CoV-2 immunoglobulins (electrochemiluminescence immunoassay) resulted positive (39.11). Two nasal swabs resulted negative, 4 weeks later. Lymphopenia persisted for 6 weeks when a typical PR appeared. IgG and IgM antibodies against HHV-6 and HHV-7 were positive. The patient was not treated.

Although literature data on the relationship PR-COVID-19 are poor, 1-5 it is possible that PR is a cutaneous manifestation related to COVID-19. 2,3,5 Although a causal relation in these cases is not assured, we would suggest the search for SARS-CoV-2 in patients with PR or PR-like eruptions living in endemic areas for COVID-19. 5 In addition, PR may appear, as in our two patients, some weeks following the first clinical manifestations of COVID-19. In these cases, it is possible that lymphopenia plays a role in viral reactivation. 1 It was demonstrated that SARS-CoV-2 induces reactivation of other viruses, such as HHV-6, HHV-7, varicella zoster virus, and EBV. 1, 4, 6, 7 In a Turkish study, 4 it was observed that the number of patients with PR and Kawasaki disease increased significantly during the COVID-19 pandemic. The authors put forward the hypothesis that this increase was related to HHV-6 reactivation by COVID-19.

Human herpesvirus-6, -7, and Epstein-Barr virus reactivation in pityriasis rosea during COVID-19

Pityriasis rosea as a cutaneous manifestation of COVID-19 infection

Erupción tipo pitiriasis rosada de Gibert en una paciente asintomática con positividad para COVID-19

The clinics of HHV-6 infection in COVID-19 pandemic: pityriasis rosea and Kawasaki disease

Pityriasis rosea-like eruption revealing COVID-19

SARS-CoV-2 as possible inducer of viral reactivations

Herpes Zoster following COVID-19: a report of three cases